PT  - JOURNAL ARTICLE
AU  - Zietz, Michael
AU  - Zucker, Jason
AU  - Tatonetti, Nicholas P.
TI  - Testing the association between blood type and COVID-19 infection, intubation, and death
AID  - 10.1101/2020.04.08.20058073
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.04.08.20058073
4099  - http://medrxiv.org/content/early/2020/09/10/2020.04.08.20058073.short
4100  - http://medrxiv.org/content/early/2020/09/10/2020.04.08.20058073.full
AB  - The rapid global spread of the novel coronavirus SARS-CoV-2 has strained healthcare and testing resources, making the identification and prioritization of individuals most at-risk a critical challenge. Recent evidence suggests blood type may affect risk of severe COVID-19. We used observational healthcare data on 14,112 individuals tested for SARS-CoV-2 with known blood type in the New York Presbyterian (NYP) hospital system to assess the association between ABO and Rh blood types and infection, intubation, and death. We found slightly increased infection prevalence among non-O types. Risk of intubation was decreased among A and increased among AB and B types, compared with type O, while risk of death was increased for type AB and decreased for types A and B. We estimated Rh-negative blood type to have a protective effect for all three outcomes. Our results add to the growing body of evidence suggesting blood type may play a role in COVID-19.Competing Interest StatementThe authors have declared no competing interest.Funding StatementMZ is funded by T15 LM007079. NPT is funded by R35GM131905Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesNYP/CUIMC Patient data is protected by HIPAA and cannot be released. However, we are releasing summary information and data from analyses. https://github.com/zietzm/abo_covid_analysis